Selected article for: "causative agent and characterization isolation"
Author: Noy-Porat, Tal; Makdasi, Efi; Alcalay, Ron; Mechaly, Adva; Levy, Yinon; Bercovich-Kinori, Adi; Zauberman, Ayelet; Tamir, Hadas; Yahalom-Ronen, Yfat; Israeli, Ma’ayan; Epstein, Eyal; Achdout, Hagit; Melamed, Sharon; Chitlaru, Theodor; Weiss, Shay; Peretz, Eldar; Rosen, Osnat; Paran, Nir; Yitzhaki, Shmuel; Shapira, Shmuel C.; Israely, Tomer; Mazor, Ohad; Rosenfeld, Ronit
Title: Tiger team: a panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes
  • Cord-id: 1wfeatf0
  • Document date: 2020_6_15
    • ID: 1wfeatf0
    Snippet: The novel highly transmissible human coronavirus SARS-CoV-2 is the causative agent of the COVID-19 pandemic. Thus far, there is no approved therapeutic drug, specifically targeting this emerging virus. Here we report the isolation and characterization of a panel of human neutralizing monoclonal antibodies targeting the SARS-CoV-2 receptor binding domain (RBD). These antibodies were selected from a phage display library constructed using peripheral circulatory lymphocytes collected from patients
    Document: The novel highly transmissible human coronavirus SARS-CoV-2 is the causative agent of the COVID-19 pandemic. Thus far, there is no approved therapeutic drug, specifically targeting this emerging virus. Here we report the isolation and characterization of a panel of human neutralizing monoclonal antibodies targeting the SARS-CoV-2 receptor binding domain (RBD). These antibodies were selected from a phage display library constructed using peripheral circulatory lymphocytes collected from patients at the acute phase of the disease. These neutralizing antibodies are shown to recognize distinct epitopes on the viral spike RBD, therefore they represent a promising basis for the design of efficient combined post-exposure therapy for SARS-CoV-2 infection.

    Search related documents:
    Co phrase search for related documents
    • acute respiratory syndrome and additional antibody: 1, 2, 3, 4
    • acute respiratory syndrome and mabs sars cov isolate: 1, 2
    • acute respiratory syndrome and mabs therapeutic efficacy: 1
    • acute respiratory syndrome and magnetic bead: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acute respiratory syndrome coronavirus and additional antibody: 1, 2, 3, 4
    • acute respiratory syndrome coronavirus and mabs sars cov isolate: 1, 2
    • acute respiratory syndrome coronavirus and mabs therapeutic efficacy: 1
    • acute respiratory syndrome coronavirus and magnetic bead: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11